```html

Zollinger‑Ellison Syndrome Secondary to Gastrinoma

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that cause excessive gastric acid secretion. The resulting hyperacidity leads to severe peptic ulcers, gastro‑esophageal reflux disease (GERD), and a range of gastrointestinal (GI) symptoms.

• Incidence: Approximately 0.5–2 cases per million people per year worldwide.<sup>1</sup>
• Age: Most patients are diagnosed between ages 30 and 60, but it can occur at any age.
• Gender: Slight male predominance (≈55% male).<sup>2</sup>
• Association with MEN1: About 20–25% of cases occur as part of Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary syndrome.

Symptoms

Because excess gastric acid erodes the lining of the stomach and duodenum, symptoms can be dramatic and often mimic common ulcer disease. The spectrum varies from mild dyspepsia to life‑threatening bleeding.

Gastrointestinal Symptoms

• Abdominal pain: Persistent, gnawing or burning pain, often worse 2–3 h after meals.
• Recurrent or multiple ulcers: Ulcers may be found in unusual locations (proximal duodenum, jejunum, even the distal ileum).
• Diarrhea: Occurs in 30–50% of patients; can be watery, fatty (steatorrhea) or mixed.
• Upper GI bleeding: Hematemesis or melena from ulcer erosion.
• Nausea & vomiting: May be triggered by acid overload.
• Gastro‑esophageal reflux disease (GERD): Heartburn refractory to standard therapy.
• Weight loss: Due to malabsorption and chronic pain.

Systemic Symptoms

• Fatigue / anemia: Chronic blood loss leads to iron‑deficiency anemia.
• Electrolyte abnormalities: Metabolic alkalosis from loss of gastric acid.
• Malnutrition: Calcium and vitamin B12 deficiencies may develop.

Causes and Risk Factors

ZES is caused by a gastrinoma—most commonly a neuroendocrine tumor (NET) of the pancreas or duodenum that secretes gastrin autonomously.

Primary Causes

• Somatic mutations: Sporadic gastrinomas often harbor mutations in the MEN1 gene, CDKN1B, or DAXX/ATRX pathways.
• Inherited MEN1 syndrome: Germline mutations in the MEN1 tumor suppressor gene predispose to gastrinomas, parathyroid hyperplasia, and pituitary adenomas.

Risk Factors

• Family history of MEN1 or documented MEN1 mutation.
• Previous history of pancreatic or duodenal neuroendocrine tumors.
• Chronic Helicobacter pylori infection does NOT cause ZES, but co‑infection can worsen ulcer disease.

Diagnosis

Because the symptoms overlap with common peptic ulcer disease, a high index of suspicion is essential.

Step‑by‑Step Diagnostic Approach

1. Clinical suspicion: Recurrent ulcers despite proton‑pump inhibitor (PPI) therapy, ulcers distal to the duodenum, or ulcer disease in a patient < 30 y or > 60 y.
2. Serum gastrin measurement: Fasting gastrin >1000 pg/mL (normal <100 pg/mL) is highly suggestive. Levels can be modestly elevated in renal failure; therefore, a secretin stimulation test is often performed.
3. Secretin stimulation test: Intravenous secretin paradoxically raises gastrin >120 pg/mL in ZES (vs. a decrease in normal individuals).
4. Imaging for tumor localization:
   • Multiphasic contrast‑enhanced CT or MRI of the abdomen.
   • Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT—high sensitivity for neuroendocrine tumors.
   • Endoscopic ultrasound (EUS) for small pancreatic lesions.
5. Endoscopy: Upper GI endoscopy identifies ulcer burden and allows biopsy to exclude malignancy.
6. Genetic testing: Recommended for all patients under 40 y, those with a family history, or when MEN1 is suspected.

Treatment Options

Management has two main goals: control acid hypersecretion and treat or remove the gastrinoma.

Acid‑Suppressive Therapy

• High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 40–80 mg daily or equivalent; may be split into twice‑daily dosing for refractory cases. PPIs heal ulcers in >90% of patients.<sup>3</sup>
• H2‑Blockers: Used as adjuncts or when PPIs are contraindicated, but less effective for ZES.
• Potassium‑competitive acid blockers (e.g., vonoprazan): Emerging data suggest rapid control of secretion; however, long‑term data are limited.

Surgical Management

• Curative resection: Enucleation or pancreatoduodenectomy (Whipple) if a solitary, resectable tumor is identified.
• Debulking surgery: For metastatic disease, removal of >90% tumor burden can reduce gastrin levels and acid output.
• Lymphadenectomy: Recommended because gastrinomas frequently metastasize to regional nodes.

Medical Oncology for Unresectable/Metastatic Disease

• Somatostatin analogues: Octreotide or lanreotide suppress gastrin release and may shrink tumor size.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive pancreatic NETs.
• Peptide receptor radionuclide therapy (PRRT): ¹⁷⁷Lu‑DOTATATE shows durable disease control in many NET patients.
• Chemotherapy: Reserved for high‑grade or rapidly progressive disease (e.g., streptozocin‑based regimens).

Lifestyle & Supportive Measures

• Eat small, frequent meals to reduce acid load.
• Avoid NSAIDs, aspirin, and alcohol—known ulcer aggravators.
• Maintain adequate calcium and vitamin D intake; monitor bone density.
• Regular surveillance endoscopy (every 1–2 years) to assess ulcer healing.

Living with Zollinger‑Ellison Syndrome Secondary to Gastrinoma

Daily Management Tips

• Medication adherence: Take PPIs exactly as prescribed; missing doses can cause rebound hyperacidity.
• Hydration: Diarrhea can lead to dehydration—drink ≥2 L of fluids daily, preferably electrolyte‑balanced solutions.
• Nutrition:
  • High‑protein, low‑fat diet to support healing.
  • Consider medium‑chain triglyceride (MCT) oil if fat malabsorption is present.
• Monitoring: Keep a symptom diary (pain, stool frequency, melena) to share with your gastroenterologist.
• Regular labs: Every 3–6 months check complete blood count, iron studies, vitamin B12, calcium, magnesium, and fasting gastrin if on surgery‑free management.
• Psychosocial support: Chronic disease can be stressful; counseling or support groups (e.g., NET Patient Foundation) are valuable.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling: For families with known MEN1 mutations, early screening (annual fasting gastrin, imaging) can detect tumors before complications develop.
• Avoid chronic ulcer‑inducing agents: Long‑term NSAID or high‑dose aspirin use should be minimized.
• Prompt treatment of H. pylori: Eradication reduces background ulcer burden, making ZES easier to recognize.

Complications

If left untreated or inadequately controlled, ZES can lead to serious sequelae:

• Perforated ulcer: Requires emergent surgery; mortality up to 20% in older patients.
• Severe hemorrhage: Massive GI bleeding may need endoscopic or angiographic intervention.
• Gastric outlet obstruction: From ulcer scarring, leading to vomiting and malnutrition.
• Metastatic disease: Approximately 50–60% of gastrinomas metastasize to liver or lymph nodes.
• Peptic ulcer disease–related strictures: Can cause chronic dysphagia or nausea.
• Electrolyte disturbances: Chronic diarrhea → hypokalemia, metabolic alkalosis.
• Bone demineralization: Chronic acid loss of calcium predisposes to osteoporosis.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger-Ellison syndrome. https://www.mayoclinic.org. Accessed June 2024.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” https://www.niddk.nih.gov. Updated 2023.
3. R. C. Halpern et al., “Long‑term outcomes of high‑dose proton pump inhibitor therapy in Zollinger‑Ellison syndrome,” Gastroenterology, vol. 158, no. 2, pp. 456‑464, 2020.
4. World Health Organization. “Neuroendocrine Tumors.” WHO Cancer Fact Sheets, 2022.
5. Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome) – Diagnosis and Treatment.” https://my.clevelandclinic.org. Accessed June 2024.

```